News Summary

• Larry Kaskel: Niacin, when added to a statin, had no cardiovascular benefit.
• The HDL dream didn’t die with niacin.
• Each drug raised HDL sky-high and still failed to reduce events.
• Billions were spent chasing a biomarker.
• We should focus on younger patients with high coronary calcium but no advanced disease.
• Use coronary CT angiography as an outcome measure.
• Name it TACTIC: Targeting Atherosclerosis Through Chlamydia-Informed Care.